Eiger BioPharmaceuticals (NASDAQ:EIGR) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a research note published on Wednesday morning. The firm issued a sell rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Stock Performance

The firm has a market cap of $2.55 million, a price-to-earnings ratio of -0.03 and a beta of 1.83. The company has a fifty day moving average of $4.85 and a 200 day moving average of $7.03. Eiger BioPharmaceuticals has a 12 month low of $1.10 and a 12 month high of $43.35.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.